Strategies for the Treatment of Acute Promyelocytic Leukemia

View More View Less
  • 1 From the Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois.

The outcome of acute promyelocytic leukemia (APL) has improved dramatically during the past 40 years. Insights into the genetic and biologic mechanisms of APL lead to the development of specific and effective therapeutic strategies. This article discusses the therapeutic interventions that transformed APL from one of the most lethal leukemias to one that is highly curable.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Olga Frankfurt, MD, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Care Center of Northwestern University, 676 North St. Clair Street, Suite 850, Chicago, IL 60611. E-mail: o-frankfurt@northwestern.edu
  • 1.

    Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977;1:549550.

    • Search Google Scholar
    • Export Citation
  • 2.

    de The H, Chomienne C, Lanotte M. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990;347:558561.

    • Search Google Scholar
    • Export Citation
  • 3.

    Kakizuka A, Miller WH Jr, Umesono K. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991;66:663674.

    • Search Google Scholar
    • Export Citation
  • 4.

    Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990;249:15771580.

    • Search Google Scholar
    • Export Citation
  • 5.

    Longo L, Pandolfi PP, Biondi A. Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. J Exp Med 1990;172:15711575.

    • Search Google Scholar
    • Export Citation
  • 6.

    de The H, Lavau C, Marchio A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991;66:675684.

    • Search Google Scholar
    • Export Citation
  • 7.

    Pandolfi PP, Grignani F, Alcalay M. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 1991;6:12851292.

    • Search Google Scholar
    • Export Citation
  • 8.

    Grimwade D, Gorman P, Duprez E. Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 1997;90:48764885.

    • Search Google Scholar
    • Export Citation
  • 9.

    Grimwade D, Howe K, Langabeer S. Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party. Br J Haematol 1996;94:557573.

    • Search Google Scholar
    • Export Citation
  • 10.

    Bolufer P, Barragan E, Sanz MA. Monitoring of minimal residual disease with the combined detection of PML/RAR alpha and RAR alpha/PML rearrangements in acute promyelocytic leukemia [in Spanish]. Med Clin (Barc) 2000;114:281285.

    • Search Google Scholar
    • Export Citation
  • 11.

    Alcalay M, Zangrilli D, Fagioli M. Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1992;89:48404844.

    • Search Google Scholar
    • Export Citation
  • 12.

    Borrow J, Goddard AD, Gibbons B. Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARA and RARA-PML fusion transcripts. Br J Haematol 1992;82:529540.

    • Search Google Scholar
    • Export Citation
  • 13.

    Chen Z, Brand NJ, Chen A. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 1993;12:11611167.

    • Search Google Scholar
    • Export Citation
  • 14.

    Redner RL, Rush EA, Faas S. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996;87:882886.

    • Search Google Scholar
    • Export Citation
  • 15.

    Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet 1997;17:109113.

    • Search Google Scholar
    • Export Citation
  • 16.

    Arnould C, Philippe C, Bourdon V. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet 1999;8:17411749.

    • Search Google Scholar
    • Export Citation
  • 17.

    Gallagher R, Mark S, Paietta E. Identification of a second acute promyelocytic leukemia (APL) patient with the STAT5b-RARalpha fusion gene among PML-RARalpha-negative Eastern Cooperative Oncology Group (ECOG) APL protocol registrants. Blood 2004;104:11.

    • Search Google Scholar
    • Export Citation
  • 18.

    Douer D, Preston-Martin S, Chang E. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood 1996;87:308313.

    • Search Google Scholar
    • Export Citation
  • 19.

    Ruiz-Arguelles GJ. Promyelocytic leukemia in Mexican Mestizos. Blood 1997;89:348349.

  • 20.

    Otero JC, Santillana S, Fereyros G. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood 1996;88:377.

    • Search Google Scholar
    • Export Citation
  • 21.

    Tomas JF, Fernandez-Ranada JM. About the increased frequency of acute promyelocytic leukemia among Latinos: the experience from a center in Spain. Blood 1996;88:2357-2358.

    • Search Google Scholar
    • Export Citation
  • 22.

    Vickers M, Jackson G, Taylor P. The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation. Leukemia 2000;14:722726.

    • Search Google Scholar
    • Export Citation
  • 23.

    Pulsoni A, Pagano L, Lo Coco F. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002;100:19721976.

    • Search Google Scholar
    • Export Citation
  • 24.

    Mele A, Stazi MA, Pulsoni A. Epidemiology of acute promyelocytic leukemia. Haematologica 1995;80:405408.

  • 25.

    Estey E, Thall P, Kantarjian H. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 1997;11:16611664.

    • Search Google Scholar
    • Export Citation
  • 26.

    Daly PA, Schiffer CA, Wiernik PH. Acute promyelocytic leukemia—clinical management of 15 patients. Am J Hematol 1980;8:347359.

  • 27.

    Jetha N. Promyelocytic leukemia with multiorgan infarctions and large-vessel thrombosis. Arch Pathol Lab Med 1981;105:683-684.

  • 28.

    Invernizzi R, Iannone AM, Bernuzzi S. Acute promyelocytic leukemia: morphological and clinical features. Haematologica 1993;78:156161.

  • 29.

    Sanz MA, Jarque I, Martin G. Acute promyelocytic leukemia. Therapy results and prognostic factors. Cancer 1988;61:713.

  • 30.

    Castoldi GL, Liso V, Specchia G, Tomasi P. Acute promyelocytic leukemia: morphological aspects. Leukemia 1994;8[suppl 2]:S27S32.

  • 31.

    Lo Coco F, Diverio D, Falini B. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999;94:1222.

    • Search Google Scholar
    • Export Citation
  • 32.

    Grignani F, Fagioli M, Alcalay M. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994;83:10.

  • 33.

    Bennett JM, Catovsky D, Daniel MT. A variant form of hypergranular promyelocytic leukemia (M3). Ann Intern Med 1980; 92(2 Pt 1):261.

  • 34.

    Rovelli A, Biondi A, Cantu Rajnoldi A. Microgranular variant of acute promyelocytic leukemia in children. J Clin Oncol 1992;10:14131418.

  • 35.

    Davey FR, Davis RB, MacCallum JM. Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol 1989;30:221227.

    • Search Google Scholar
    • Export Citation
  • 36.

    Tallman MS, Kim HT, Schiffer CA. Microgranular variant (M3v) of acute promyelocytic leukemia (APL) does not have a worse prognosis than classical APL in the ATRA era: a report of 153 patients treated on Intergroup 0129 and Pethema APL96 and APL99. Blood 2004;104:394.

    • Search Google Scholar
    • Export Citation
  • 37.

    Grimwade D. The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. Br J Haematol 1999;106:591613.

    • Search Google Scholar
    • Export Citation
  • 38.

    Tallman MS, Andersen JW, Schiffer CA. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002;100:42984302.

    • Search Google Scholar
    • Export Citation
  • 39.

    Asou N, Adachi K, Tamura U. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol 2001;48[suppl 1]:S65S71.

    • Search Google Scholar
    • Export Citation
  • 40.

    Au WY, Fung A, Chim CS. FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact. Br J Haematol 2004;125:463469.

    • Search Google Scholar
    • Export Citation
  • 41.

    Sanz MA, Lo Coco F, Martin G. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000;96:12471253.

    • Search Google Scholar
    • Export Citation
  • 42.

    Jurcic JG, Nimer SD, Scheinberg DA. Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 2001;98:26512656.

    • Search Google Scholar
    • Export Citation
  • 43.

    Ito S, Ishida Y, Oyake T. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia. Leuk Lymphoma 2004;45:17831789.

    • Search Google Scholar
    • Export Citation
  • 44.

    Murray CK, Estey E, Paietta E. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol 1999;17:293297.

    • Search Google Scholar
    • Export Citation
  • 45.

    Lee JJ, Cho D, Chung IJ. CD34 expression is associated with poor clinical outcome in patients with acute promyelocytic leukemia. Am J Hematol 2003;73:149153.

    • Search Google Scholar
    • Export Citation
  • 46.

    Candoni A, Damiani D, Michelutti A. Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia. Eur J Haematol 2003;71:18.

    • Search Google Scholar
    • Export Citation
  • 47.

    Chim CS, Wong SY, Kwong YL. Aberrant gene promoter methylation in acute promyelocytic leukaemia: profile and prognostic significance. Br J Haematol 2003;122:571578.

    • Search Google Scholar
    • Export Citation
  • 48.

    Bolognesi E, Cimino G, Diverio D. HLA class I in acute promyelocytic leukemia (APL): possible correlation with clinical outcome. Leukemia 2000;14:393398.

    • Search Google Scholar
    • Export Citation
  • 49.

    Fenaux P, Chastang C, Chevret S. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94:11921200.

    • Search Google Scholar
    • Export Citation
  • 50.

    Ades L, Chevret S, De Botton S. Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia 2005;19:230233.

    • Search Google Scholar
    • Export Citation
  • 51.

    Vahdat L, Maslak P, Miller WH Jr. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994;84:38433849.

    • Search Google Scholar
    • Export Citation
  • 52.

    Gallagher RE, Willman CL, Slack JL. Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 1997;90:16561663.

    • Search Google Scholar
    • Export Citation
  • 53.

    Gupta V, Yib QL, Brandwein J. Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy. Leuk Lymphoma 2004;45:469480.

    • Search Google Scholar
    • Export Citation
  • 54.

    Ferrara F, Morabito F, Martino B. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 2000;18:12951300.

    • Search Google Scholar
    • Export Citation
  • 55.

    De Botton S, Chevret S, Sanz M. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol 2000;111:801806.

    • Search Google Scholar
    • Export Citation
  • 56.

    Grimwade D, Walker H, Oliver F. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:23222333.

    • Search Google Scholar
    • Export Citation
  • 57.

    Schoch C, Haase D, Haferlach T. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol 1996;94:493500.

    • Search Google Scholar
    • Export Citation
  • 58.

    Cervera J, Martin G, Hernandez J. Additional chromosome abnormalities have no prognostic value in acute promyelocytic leukemia patients treated with simultaneous ATRA and anthracycline-based chemotherapy: an update of the APL96 and APL99 Pethema protocols. Blood 2004;104:2019.

    • Search Google Scholar
    • Export Citation
  • 59.

    Kiyoi H, Naoe T, Yokota S. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1997;11:14471452.

    • Search Google Scholar
    • Export Citation
  • 60.

    Kainz B, Heintel D, Marculescu R. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). Hematol J 2002;3:283289.

    • Search Google Scholar
    • Export Citation
  • 61.

    Shih LY, Kuo MC, Liang DC. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer 2003;98:12061216.

    • Search Google Scholar
    • Export Citation
  • 62.

    Noguera NI, Breccia M, Divona M. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 2002;16:21852189.

    • Search Google Scholar
    • Export Citation
  • 63.

    Grimwade D, Gale RE, Hills R. The relationship between FLT3 mutation status, biological characteristics and outcome in patients with acute promyelocytic leukemia. Blood 2003;102.

    • Search Google Scholar
    • Export Citation
  • 64.

    Callens C, Chevret S, Cayuela JM. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia 2005;19:11531160.

    • Search Google Scholar
    • Export Citation
  • 65.

    Tallman MS, Brenner B, Serna Jde L. Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. Leuk Res 2005;29:347351.

    • Search Google Scholar
    • Export Citation
  • 66.

    Dally N, Hoffman R, Haddad N. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients. Thromb Res 2005;116:109114.

    • Search Google Scholar
    • Export Citation
  • 67.

    Sanz MA, Martin G, Rayon C. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999;94:30153021.

    • Search Google Scholar
    • Export Citation
  • 68.

    Sanz MA, Martin G, Gonzalez M. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004;103:12371243.

    • Search Google Scholar
    • Export Citation
  • 69.

    Sanz MA, Tallman MS, Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 2005;105:30193025.

    • Search Google Scholar
    • Export Citation
  • 70.

    Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998;91:30933102.

    • Search Google Scholar
    • Export Citation
  • 71.

    Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002;99:759767.

  • 72.

    Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 2003;17:14541463.

    • Search Google Scholar
    • Export Citation
  • 73.

    Bernard J, Weil M, Boiron M. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 1973;41:489496.

  • 74.

    Marty M, Ganem G, Fischer J. Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin [in French]. Nouv Rev Fr Hematol 1984;26:371378.

    • Search Google Scholar
    • Export Citation
  • 75.

    Avvisati G, Petti M, Lo Coco F. AIDA: The Italian way of treating acute promyelocytic leukemia (APL), final act [abstract]. Blood 2003;102:142a.

    • Search Google Scholar
    • Export Citation
  • 76.

    Petti MC, Avvisati G, Amadori S. Acute promyelocytic leukemia: clinical aspects and results of treatment in 62 patients. Haematologica 1987;72:151155.

    • Search Google Scholar
    • Export Citation
  • 77.

    Avvisati G, Mandelli F, Petti MC. Idarubicin (4-demethoxy-daunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur J Haematol 1990;44:257260.

    • Search Google Scholar
    • Export Citation
  • 78.

    Head D, Kopecky KJ, Weick J. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 1995;86:17171728.

  • 79.

    Avvisati G, Petti MC, Lo-Coco F. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 2002;100:31413146.

    • Search Google Scholar
    • Export Citation
  • 80.

    Ades L, Raffoux E, Chevret S. Is ARAC required in the treatment of newly diagnosed APL? Results of a randomised trial (APL 2000). Blood 2004;104.

    • Search Google Scholar
    • Export Citation
  • 81.

    Huang ME, Ye YC, Chen SR. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567572.

  • 82.

    Castaigne S, Chomienne C, Daniel MT. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76:17041709.

    • Search Google Scholar
    • Export Citation
  • 83.

    Warrell RP Jr, Frankel SR, Miller WH Jr. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-transretinoic acid). N Engl J Med 1991;324:13851393.

    • Search Google Scholar
    • Export Citation
  • 84.

    Chen ZX, Xue YQ, Zhang R. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991;78:14131419.

    • Search Google Scholar
    • Export Citation
  • 85.

    Fenaux P, Castaigne S, Dombret H. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992;80:21762181.

    • Search Google Scholar
    • Export Citation
  • 86.

    Tallman MS, Andersen JW, Schiffer CA. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:10211028.

  • 87.

    Fenaux P, Le Deley MC, Castaigne S. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993;82:32413249.

    • Search Google Scholar
    • Export Citation
  • 88.

    Fenaux P, Chevret S, Guerci A. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia 2000;14:13711377.

    • Search Google Scholar
    • Export Citation
  • 89.

    Estey E, Thall PF, Pierce S. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997;15:483490.

  • 90.

    Burnett AK, Grimwade D, Solomon E. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999;93:41314143.

    • Search Google Scholar
    • Export Citation
  • 91.

    Frankel SR, Eardley A, Heller G. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med 1994;120:278286.

    • Search Google Scholar
    • Export Citation
  • 92.

    De Botton S, Dombret H, Sanz M. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1998;92:27122718.

    • Search Google Scholar
    • Export Citation
  • 93.

    Wiley JS, Firkin FC. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. Leukemia 1995;9:774778.

    • Search Google Scholar
    • Export Citation
  • 94.

    Avvisati G, Lo Coco F, Diverio D. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996;88:13901398.

    • Search Google Scholar
    • Export Citation
  • 95.

    Santos FL, Dore AI, Lima AS. Hematological features and expression profile of myeloid antigens of acute promyelocytic leukemia patients: analysis of prognostic factors for development of the retinoic acid syndrome [in Portuguese]. Rev Assoc Med Bras 2004;50:286292.

    • Search Google Scholar
    • Export Citation
  • 96.

    Fenaux P, Castaigne S, Chomienne C. All trans retinoic acid treatment for patients with acute promyelocytic leukemia. Leukemia 1992;6[suppl 1]:6466.

    • Search Google Scholar
    • Export Citation
  • 97.

    Tallman MS, Andersen JW, Schiffer CA. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000;95:9095.

    • Search Google Scholar
    • Export Citation
  • 98.

    Sanz MA, Lo Coco F. Standard practice and controversial issues in front-line therapy of acute promyelocytic leukemia. Haematologica 2005;90:840845.

    • Search Google Scholar
    • Export Citation
  • 99.

    Mandelli F, Diverio D, Avvisati G. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997;90:10141021.

    • Search Google Scholar
    • Export Citation
  • 100.

    Gallagher RE, Yeap BY, Bi W. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003;101:25212528.

    • Search Google Scholar
    • Export Citation
  • 101.

    Lo-Coco F, Breccia M, Diverio D. The importance of molecular monitoring in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003;16:503520.

    • Search Google Scholar
    • Export Citation
  • 102.

    Diverio D, Rossi V, Avvisati G. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter ``AIDA'' trial. GIMEMA-AIEOP Multicenter ``AIDA'' Trial. Blood 1998;92:784789.

    • Search Google Scholar
    • Export Citation
  • 103.

    Lo Coco FA, Avvisati G, Vignetti M. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation: results of the AIDA-2000 trial of the Italian GIMEMA group. Blood 2004;104:392.

    • Search Google Scholar
    • Export Citation
  • 104.

    Lengfelder E, Reichert A, Schoch C. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 2000;14:13621370.

    • Search Google Scholar
    • Export Citation
  • 105.

    Asou N, Adachi K, Tamura J. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998;16:7885.

    • Search Google Scholar
    • Export Citation
  • 106.

    Kantarjian HM, Keating MJ, Walters RS. Role of maintenance chemotherapy in acute promyelocytic leukemia. Cancer 1987;59:12581263.

  • 107.

    Muindi JR, Frankel SR, Huselton C. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 1992;52:21382142.

    • Search Google Scholar
    • Export Citation
  • 108.

    Muindi J, Frankel SR, Miller WH Jr. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid ``resistance'' in patients with acute promyelocytic leukemia. Blood 1992;79:299303.

    • Search Google Scholar
    • Export Citation
  • 109.

    Ohno R, Asou N. The recent JALSG study for newly diagnosed patients with acute promyelocytic leukemia (APL). Ann Hematol 2004:83[suppl 1]:S77S78.

    • Search Google Scholar
    • Export Citation
  • 110.

    Wang Z, Sun G, Shen Z. Differentiation therapy for acute promyelocytic leukemia with all-trans retinoic acid: 10-year experience of its clinical application. Chin Med J (Engl) 1999;112:963967.

    • Search Google Scholar
    • Export Citation
  • 111.

    Soignet SL, Maslak P, Wang ZG. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:13411348.

    • Search Google Scholar
    • Export Citation
  • 112.

    Soignet SL, Frankel SR, Douer D. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:38523860.

    • Search Google Scholar
    • Export Citation
  • 113.

    Dombret H, Fenaux P, Soignet SL, Tallman MS. Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 2002;39[suppl 1]:813.

    • Search Google Scholar
    • Export Citation
  • 114.

    Lazo G, Kantarjian H, Estey E. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer 2003;97:22182224.

    • Search Google Scholar
    • Export Citation
  • 115.

    Shalabi A, Fallavollita A, Cheson BD. Arsenic trioxide in relapsed or refractory acute promyelocytic leukemia: an NCI special exception (compassionate use) program [abstract]. Blood 2001;98:596a.

    • Search Google Scholar
    • Export Citation
  • 116.

    Camacho LH, Soignet SL, Chanel S. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000;18:26202625.

    • Search Google Scholar
    • Export Citation
  • 117.

    Zhang P. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. J Biol Regul Homeost Agents 1999;13:195200.

    • Search Google Scholar
    • Export Citation
  • 118.

    Niu C, Yan H, Yu T. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94:33153324.

    • Search Google Scholar
    • Export Citation
  • 119.

    Au WY, Chim JC, Lie AK. Treatment of relapsed acute promyelocytic leukemia by arsenic-based strategies without hematopoietic stem cell transplantation in Hong Kong: a seven-year experience. Blood 2004;104:395.

    • Search Google Scholar
    • Export Citation
  • 120.

    Douer D, Hu W, Giralt S. Arsenic trioxide (Trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 2003;8:132140.

    • Search Google Scholar
    • Export Citation
  • 121.

    Leoni F, Gianfaldoni G, Annunziata M. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation. Haematologica 2002;87:485489.

    • Search Google Scholar
    • Export Citation
  • 122.

    Mathews V, Balasubramanian P, Shaji RV. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol 2002;70:292299.

    • Search Google Scholar
    • Export Citation
  • 123.

    Ghavamzadeh A, Alimoghaddam N, Aghdami M. Treatment of new cases of acute promyelocytic leukemia by arsenic trioxide. Presented at the American Society of Clinical Oncology 39th Annual Meeting; May 31–June 3, 2003; Chicago, IL.

    • Search Google Scholar
    • Export Citation
  • 124.

    George B, Mathews V, Vishwabandhya A. Arsenic trioxide (As2O3) in the treatment of patients with newly diagnosed acute promyelocytic leukemia (APML)—toxicity and outcome. Blood 2004;104:889.

    • Search Google Scholar
    • Export Citation
  • 125.

    Mathews V, George B, Lakshmi K. Hepatotoxicity profile of single agent As2O3 in the management of newly diagnosed cases of acute promyelocytic leukemia: Impact on outcome and correlation with genetic polymorphisms. Blood 2005;106:262a.

    • Search Google Scholar
    • Export Citation
  • 126.

    Ghavamzadeh A, Alimoghaddam K, Ghaffari H. Treatment of new cases of acute promyelocytic leukemia by arsenic trioxide. Blood 2004;104:396.

  • 127.

    Hu J, Liu Y-F, Zhu Y-M. A 3-year follow-up of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) as front line therapy for newly diagnosed acute promyelocytic leukemia (APL). Blood 2005;106:260a.

    • Search Google Scholar
    • Export Citation
  • 128.

    Shen ZX, Shi ZZ, Fang J. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004;101:53285335.

    • Search Google Scholar
    • Export Citation
  • 129.

    Estey E, Faderl S, Giles F. All-trans retinoic acid (ATRA) + arsenic trioxide (ATO) to minimize or eliminate chemotherapy in untreated APL [abstract]. Blood 2003;102:618a619a.

    • Search Google Scholar
    • Export Citation
  • 130.

    Estey E, Garcia-MAnero G, Ferrajoli A. Use of all-trans retinoic acid (ATRA) + arsenic trioxide (ATO) to eliminate or minimize use of chemotherapy (CT) in untreated acute promyelocytic leukemia. Blood 2004;104:393.

    • Search Google Scholar
    • Export Citation
  • 131.

    Che-Pin L, Huang MJ, Chang IY. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia. Leuk Lymphoma 2000;38:195198.

    • Search Google Scholar
    • Export Citation
  • 132.

    Ohnishi K, Yoshida H, Shigeno K. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000;133:881885.

    • Search Google Scholar
    • Export Citation
  • 133.

    Unnikrishnan D, Dutcher JP, Varshneya N. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001;97:15141516.

    • Search Google Scholar
    • Export Citation
  • 134.

    Westervelt P, Brown RA, Adkins DR. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001;98:266271.

    • Search Google Scholar
    • Export Citation
  • 135.

    Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 2003;21:36093615.

    • Search Google Scholar
    • Export Citation
  • 136.

    Douer DT, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005;23:23962410.

    • Search Google Scholar
    • Export Citation
  • 137.

    Huang SY, Chang CS, Tang JL. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 1998;103:10921095.

    • Search Google Scholar
    • Export Citation
  • 138.

    Takeshita A, Shinjo K, Naito K. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia 2005;19:13061311.

    • Search Google Scholar
    • Export Citation
  • 139.

    Lo-Coco F, Cimino G, Breccia M. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004;104:19951999.

    • Search Google Scholar
    • Export Citation
  • 140.

    Estey EH, Giles FJ, Beran M. Experience with gemtuzumab ozogamycin (``mylotarg'') and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002;99:42224224.

    • Search Google Scholar
    • Export Citation
  • 141.

    Mandelli F, Labopin M, Granena A. European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working party on acute leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT). Bone Marrow Transplant 1994;14:293298.

    • Search Google Scholar
    • Export Citation
  • 142.

    de Botton S, Fawaz A, Chevret S. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 2005;23:120126.

    • Search Google Scholar
    • Export Citation
  • 143.

    Ferrara F, Palmieri S, Annunziata M. Prolonged molecular remission after autologous stem cell transplantation in relapsed acute promyelocytic leukemia. Haematologica 2004;89:621622.

    • Search Google Scholar
    • Export Citation
  • 144.

    Lo-Coco F, Romano A, Mengarelli A. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia 2003;17:19301933.

    • Search Google Scholar
    • Export Citation
  • 145.

    Iguchi T, Yokoyama K, Miyamoto K. Successful bone marrow transplantation with a matched unrelated donor in an acute promyelocytic leukemia patient after reinduction therapy with arsenic trioxide [in Japanese]. Rinsho Ketsueki 2004;45:7577.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 98 71 6
PDF Downloads 26 20 1
EPUB Downloads 0 0 0